A 12-week Double-blind, Multicentre, Randomised, Active-controlled, 2-arm, Parallel-group Clinical Trial to Evaluate the Safety of CHF5993 pMDI 200/6/12.5 μg HFA-152a, Compared to CHF5993 pMDI 200/6/12.5 μg HFA-134a, in Subjects With Asthma.
A 12-week Double-blind, Multicentre, Randomised, Active-controlled, 2-arm, Parallel-group Clinical Trial to Evaluate the Safety of CHF5993 pMDI 200/6/12.5 μg HFA-152a, Compared to CHF5993 pMDI 200/6/12.5 μg HFA-134a, in Subjects With Asthma.
The CLI-05993AB6-03 Study is an interventional study designed to investigate the safety and efficacy of a new low global warming potential propellant (HFA-152a) compared to the currently approved one (HFA-134a) in the medication (CHF5993) in patients with moderate to severe asthma
Outpatients attending the hospital clinics/study centers will be recruited. Moderate to severe controlled asthma adult subjects will be recruited. A total of 513 subjects will be randomised. The whole study will last approximately 16 weeks for each subject.
Inclusion Criteria:
Exclusion Criteria:
Rousse, 7002, Bulgaria
Rousse, 7002, Bulgaria
Sofia, 1142, Bulgaria
Frankfurt, 60596, Germany
Genova, 16132, Italy
Messina, 98125, Italy
Bialystok, 15-276, Poland
Ostrowiec Świętokrzyski, 27-400, Poland
Craiova, 200515, Romania
Timișoara, Romania
Santiago de Compostela, 15706, Spain
Manchester, M23 9QZ, United Kingdom